Clinical Trials Logo

Filter by:
NCT ID: NCT03012646 Withdrawn - Clinical trials for Chronic Obstructive Pulmonary Disease

Safety and Tolerability of Inhaled Treprostinil in Adult PH Due to COPD

Start date: April 2017
Phase: Phase 2
Study type: Interventional

This is a multicenter, single-arm trial to evaluate the safety and efficacy of inhaled treprostinil in subjects with pre-capillary pulmonary hypertension (PH) associated with Chronic Obstructive Pulmonary Disease (COPD).

NCT ID: NCT03019094 Withdrawn - Overactive Bladder Clinical Trials

Overactive Bladder Posterior Tibial Implantable MIcro STimulator - 1

OPTIMIST-1
Start date: April 2017
Phase: N/A
Study type: Interventional

Interventional, Prospective, Open Label study

NCT ID: NCT03053284 Withdrawn - Hyperinsulinism Clinical Trials

Pasireotide in Hyperinsulinemic Hypoglycemia

Start date: April 2017
Phase: Phase 2
Study type: Interventional

This is a small controlled pilot study to assess the effect of subcutaneous pasireotide on preventing hypoglycemia due to hyperinsulinism, including congenital hyperinsulinism and insulinoma.

NCT ID: NCT03084978 Withdrawn - Aortic Stenosis Clinical Trials

Conscious Sedation vs General Anesthesia in TAVR Patients

Start date: April 2017
Phase: N/A
Study type: Interventional

This is a randomized controlled trial investigating the effect of general anesthesia versus conscious sedation on operative times in patients undergoing transcatheter aortic valve replacement.

NCT ID: NCT03132441 Withdrawn - Heart Failure Clinical Trials

Cardiac Rehab for Advanced Heart Failure-LVAD Candidates

Start date: April 2017
Phase: N/A
Study type: Interventional

This study is a pilot study evaluating the feasibility and early efficacy of cardiac rehabilitation to improve frailty and symptoms in patients with advanced heart failure (NYHA class III-IV), who are being considered for LVAD therapy.

NCT ID: NCT03263533 Withdrawn - Schizophrenia Clinical Trials

HDAC Inhibitor Augmentation to Clozapine

Start date: April 2017
Phase: Early Phase 1
Study type: Interventional

The main goal of this pilot study is to test the extent to which adjunctive treatment with the histone deacetylase (HDAC) inhibitor vorinostat improves brain plasticity and cognition in a pilot placebo-controlled trial in patients with schizophrenia who are on clozapine.

NCT ID: NCT03271970 Withdrawn - Clinical trials for Conductive Hearing Loss

The Anatomic Determinants of Perforation Induced Hearing Loss

Start date: April 2017
Phase: N/A
Study type: Observational

The purpose of this study is to identify factors that may contribute to conductive hearing loss. Conductive hearing loss is a type that is due to a problem with the outer or middle ear. Because of this, sound does not travel through the ear normally. Perforated tympanic membranes of study patients will be photographed during the patient's routine visit using a digital otoscope. These pictures will be used to analyze perforation size as an absolute value as well as a percentage of the tympanic membrane. Audiometric results and CT scans of temporal bone (reports and images) collected as standard of care will be evaluated. Images of CT scans will be imported into a medical imaging software for creation of anatomically realistic 3D models of the middle ear and mastoid air space. Structural analysis on each 3D model will be conducted and analyzed, the volume of middle ear and mastoid air spaces will be recorded, and data points will be correlated with perforation size and location to audiogram results.

NCT ID: NCT01977911 Withdrawn - Tracheal Stenosis Clinical Trials

Clinical Trial of Stem Cell Based Tissue Engineered Laryngeal Implants

RegenVOX
Start date: April 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This study aims to test a new groundbreaking treatment for narrowing of the voicebox and upper windpipe, which can be due to injury, inflammatory disease or cancer treatment. Narrowing of the voicebox or upper windpipe can leave patients dependant on a tracheostomy tube to breath through (a tube or hole in the neck), which can require a high level of care with regular hospital visits and can lead to recurrent chest infections. Regular surgical procedures may be necessary to widen the airway. Speaking may be very difficult or not even possible, breathing is usually a struggle and swallowing can also be affected. Patients feel very tired all the time. The new treatment tested by this study is an implant that will partially replace the voicebox or upper windpipe in order to cure the narrowing. The implant is based on a human donor voicebox or windpipe that has been processed with detergents and enzymes in order to remove all the cells from the donor, leaving a 'scaffold' of connective tissue. The patient's own stem cells are removed from the bone marrow, then are grown on the scaffold in the laboratory. These cells will form the cartilage in the wall of the scaffold. A split skin graft from the patient may be needed to line the inside of the implant. The implant can be considered 'living' due to the cells grown on it, and this type of treatment is referred to as 'tissue engineering' or 'regenerative medicine'. Once these cells have attached and started to grow on the scaffold, it is ready to be implanted into the patient, and an operation is performed which occurs in two separate stages. The final stage of the operation involves removing the narrow section of voicebox or upper windpipe and implanting the scaffold to reconstruct it. Patients will be followed up for two years after this operation, with investigations such as CT scans, examination of the voicebox and windpipe with a flexible camera (bronchoscopy) and blood tests performed at specific times. It is intended that this treatment will significantly improve patients' symptoms resulting in better breathing, swallowing and voice function, reducing the need for repeated hospital visits and procedures and enhancing patients' quality of life.

NCT ID: NCT02545361 Withdrawn - Lymphoma Clinical Trials

Safety, Tolerability, and Anti-cancer Activity of KAHR-102 (The Study Drug) for the Treatment of Lymphoma Patients

Start date: April 2018
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and to determine the Dose Limiting Toxicity (DLT) and the Maximal Tolerated Dose (MTD) of KAHR-102.

NCT ID: NCT02977689 Withdrawn - Glioma Clinical Trials

Trial of IDH305 in IDH1 Mutant Grade II or III Glioma

Start date: April 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to found out if the drug IDH305 is safe and effective in subjects with IDH1 mutant grade II or III glioma that has progressed after observation or radiation therapy.